Member Info for RuckRover

Is that based on news or analysis or just a ramp?

TF,

This was the announcement regarding the Nottingham Uni Scancell collaboration on Gioblastoma

https://www.scancell.co.uk/immunobody®-vaccine-to-be-developed-for-the-treatment-of-glioblastoma-multiforme

It dates back to 2016 - I haven't managed to find any news since, maybe someone else can?

C11,

I have to agree with you (and Paul) on the incessant posts of companies, treatments, licensing deals, takeovers which have little or no relevance to Scancell. It is not only embarrassing but smacks of desperation.

One of the worst culprits is on the other channel who when pulled up by Bermuda admitted "I absolutely agree Bermuda. I simply copied the article". The article in question stated a product launch date for Immunobody and Moditope as 2024. This shows completion ignorance of the biotech section, the drug development/approval process, Scancell and its products. The article also implies enough cash to keep them going for years which we all know just isn't true. Yet the article was "simply copied" and pasted on the Scancell BB.

When someone posts an article there is an implied endorsement/agreement. It is rare that an article or post will be 100% agreed or 100% disagreed with - there will be points of agreement and disagreement to a greater or lessor extent. So in the case of the article referenced above a comment like "they have identified this as a high risk investment but with healthy returns should it all come good. However their assessment of cash runway is very optimistic and a launch date of 2024 is ludicrous. TD for example, quote 2029 for immunobody and Moditope and 2030 for Glymab and Avidimab."

So fewer but more relevant posts would get my vote!

WTP,

"Ruck...the perfect trader. You should write a book."

Firstly, there's no such thing as a perfect trader.

Secondly, there are plenty of books written already with advice on investing. Funnily enough, none of them advocate going all in on a single share and stagnating cash for 10 years or more. If you choose to ignore sound advice and principles that is your affair and the consequences are down to you alone.

crumbs,

7p pint - was I drunk when I made that bet?

Ray,

"Today 13:16

You can't buy or sell solely on the results of one patient. "

Why not - I did.

When the positive news came last year I waited for the price to rise and sold.

When the negative news (as presented by crumbs) I waited for the price to drop and bought.

Wtp,

You mean closing deals - I agree.

Ciaskin,

Thanks for the very pertinent question.

burble,

Thanks for the response.

"I would argue that rapid initial 50% tumor reduction would certainly interest big pharma"

Not if it grows back surely?

TF,

The humour bypass was a success then?

TF,

"Ruck NO it wasn't greeted that way !!"

You are of course just as entitled to your opinion as anyone. In my opinion, however, I thought the response was muted to say the least. I don't think anyone expressed the thought it was ultra positive (other than yet another inflection point prediction), there were a couple of negatives (performance at last company and the number of job swaps in 15 years) and the effect on the SP was, er, zero.

You call that "balanced interest" I call it apathetic. Perhaps indifference would have been a better word?

In any event, even if the response was indifferent, muted, apathetic or "balanced" it doesn't really matter. Scancell's success will be determined by what the drugs do in patients not who counts the beans.

Yes, the RNS was two days ago.

The news was greeted with raging apathy.

Chelsea,

What about a smiley face emoji below the hands as well?

Crumbs,

I think the danger of falling of a cliff has passed once you are already at the bottom.

TF,

Should I order the "2024 Pivotal Year" T-Shirt run now?

Green453,

Yes it is easy to get your head in a spin anticipating when and what the next news will be, analysing every buy/sell and movement (or otherwise) with other companies.

Personally I think all we need do is concentrate on the items contained in the June 10th RNS "Pipeline strategy and business update". Here, Scancell state that they will focus on two assets:

SCIB1 (or iSCIB1+) and MODI1. They estimate updates as follows:

SCIB1

"The trial is progressing well, with 73% of the required number of patients receiving SCIB1 in combination with two checkpoint inhibitors (ipilimumab and nivolumab) recruited to date. Scancell expects the initial topline data readout from this double checkpoint arm of the study in Q4 2023. "

MODI1

"Additionally, Scancell has recruited a fourth cohort of three patients receiving full dose Modi-1 in combination with the checkpoint inhibitor nivolumab. Subject to a safety committee review meeting scheduled to take place in August, this cohort will be expanded to 21 patients in both head and neck and renal cancer. Preliminary topline data from these cohorts is expected to be reported in 2024."

Despite their focus on these two assets, they couldn't get away without mentioning:

Antibody platform

"Scancell has developed a novel technology platform for producing monoclonal antibodies that recognise glycans with high specificity and affinity. The platform has generated revenues and the antibodies continue to yield compelling results which have led to a new 6-month evaluation by a leading Biotech company. Additional in-house data has illustrated the potential of our antibodies as chimeric antigen receptor T cell (CART) therapies providing the data for a deal with a cell therapy company. These results along with updates on SCIB1 and Modi-1 will be presented at the AACR-CIMT meeting in Milan in September 2023."

So, SCIB1 data Q4 2023, MODI1 data 2024 with possible updates at AACR Milan in September.

Any news on anything else would be a bonus with any revenue earning potential going towards funding the two main assets.

"Is this anything to do with Scancell?"

Obviously not. It's about cancer being eradicated in a hard to treat cancer using an experimental immunotherapy drug. The target is not one of Scancell's (yet anyway) and the financial rewards will not be coming to Scancell shareholders.

We need to maintain the boundaries and work for the financial benefit of a few big corporations. If there were any sharing of ideas, collaboration , data, resources, acknowledgement that there could be merit in different approaches, there may be a real danger of actually curing people.

WTP,

And what about the rampers?

If you examined the facts rather than be in denial, you would realise that Crackin is one of the few here that has called it correctly.

Douve,

" So i cant understand the argument that we would have had a less severe drop without the trish news."

I have to agree with AB here. Without the Trish news the sp wouldn't have climbed so high so wouldn't have had as far to fall.

I think the polarisation of opinion and sentiment does lend itself to higher highs and lower lows.

C7,

You were right to not be sure about Mondays. It is in fact the second most likely day for news after Tuesday.

Wtp,

" We all have cool embroidered leather jackets with "Team Ramp" written on the back, and a secret handshake."

I'd suspected as much for a while now but thanks for confirming.

It is interesting to observe then going arguments centred around who is "right" and "wrong"

Anyone can pick a moment in time and prove they were right and others were wrong.

Just because a share price falls it doesn't Necessarily follow that holding is "wrong". Warren Buffet is probably the best example of a long term holder. He says "never buy a share you are not prepared to hold for 20 years". (Scancell will soon fall into that bracket for me!)

But equally, if someone chooses to trade, that's not "wrong" either. It's just a different strategy.

Presumably, all investors here want to make money? There are multiple ways of doing that, perhaps some more effective than others, but each to their own.